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The peptidase inhibitor PI16 was identified previously using microarray analysis as being 
over-expressed by CD4-positive/CD25-positive Treg compared with CD4-
positive/CD25-negative Th cells. Using a monoclonal antibody to the human PI16 
protein, we found that the PI16-positive Treg have a memory (CD45RO-positive) 
phenotype, and express higher levels of FOXP3 than PI16-negative Treg. The PI16-
positive Treg are functional in in vitro suppressor assays and have similar potency to 
PI16-negative Treg. The chemokine receptors CCR4 and CCR6 are expressed by more of 
the PI16-positive CD45RO-positive Treg compared to PI16-negative CD45RO-positive 
Treg or other PI16-positive Th cells. The PI16-positive Treg showed enhanced in vitro 
migration towards the chemokines CCL17 and CCL20, suggesting they can migrate to 
sites of inflammation. We conclude that PI16 identifies a distinct subset of functional 
memory Treg which can migrate to the sites of inflammation and regulate the pro-
inflammatory response at those sites. 
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Regulatory T cells (Treg) are critical for maintaining tolerance and immune homeostasis 
[1], and the manipulation of Treg numbers or function is seen as a potential strategy for 
the treatment of autoimmune diseases and graft-versus-host disease [2; 3]. The expression 
of the transcription factor FOXP3 is a defining characteristic of Treg [4; 5], but viable 
Treg cannot be isolated based on their expression of FOXP3, as detection of the protein 
requires the permeabilisation of the cells [6; 7].  
 
The expression of high levels of the interleukin 2 receptor alpha chain (CD25) by CD4-
positive lymphocytes is widely used as a surrogate marker for FOXP3 expression to 
identify Treg [8; 9]. The effectiveness of approach is, however, limited as CD25 
expression is also upregulated during T cell activation [10; 11]. More recently, the 
expression of high levels of CD25 and low levels of the interleukin 7 receptor alpha chain 
(CD127) has also been used to isolate functional Treg [12; 13]. Again, this approach may 
be limited, as the expression of CD127 is also reduced following T cell activation [14]. 
Neither of these combinations is able to define a population of CD4-positive lymphocytes 
in which all the cells express FOXP3. As FOXP3 is expressed by several functionally 
distinct subsets of CD4-positive lymphocytes [15; 16], additional cell surface markers are 
necessary to identify, isolate and characterise pure populations of viable Treg.  
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In the course of genome wide expression profiling to identify the genes regulated by 
FOXP3 in human Treg, and identify novel candidate surface proteins specific to human 
Treg, we identified the peptidase inhibitor PI16 (PI16) as being over-expressed by in 
vitro expanded Treg derived from cord blood, compared to T helper (Th) cells from the 
same source [17].  
 
The peptidase inhibitor 16 (PI16; also called CRISP-9 or PSPBP) is a member of the 
cysteine-rich secretory protein (CRISP) family. The mature PII6 protein is a 436 amino 
acid polypeptide with three N-linked glycosylation motifs, which is predicted to localize 
to the plasma membrane through a GPI anchor [18]. PI16 has been identified as a binding 
protein for “prostate secretory protein of 94 amino acids” (PSP94), and serum levels of 
PSP94 and PI16 have been identified as biomarkers of recurrence risk in prostate cancer 
[19], but the expression of PI16 by immune cells has not been reported previously. 
 
The differential expression of PI16 by peripheral blood Treg compared to Th cells was 
confirmed by qRT-PCR, and cell surface expression was demonstrated by flow cytometry 
using polyclonal antibodies to human PI16 [17]. To evaluate the potential of PI16 as a 
marker for circulating Treg, we generated a mouse monoclonal antibody to the human 
PI16 protein. Here we describe the phenotype and function of the PI16-expressing Treg 




2. Materials and Methods: 
 
2.1 PBMC Isolation 
Peripheral blood was collected using lithium-heparin anticoagulant from healthy adult 
volunteers who gave informed consent, under ethics clearance from the Research Ethics 
Committee of the Children’s, Youth and Women’s Health Service, South Australia (REC 
2007/11/2010). Mononuclear cells (PBMC) were isolated by density centrifugation over 
Lymphoprep (Axis-Shield, Oslo, Norway) using standard protocols.  
 
2.2 Antibodies and Chemokines 
A mouse polyclonal antibody raised to full-length recombinant PI16 protein was 
purchased from Abnova (Taipei City, Taiwan). Monoclonal antibodies to CD3, CD4, 
CD8, CD19, CD25, CD127, CD154, CD45RA, CD45RO, CCR4, CCR6, the Treg 
cocktail (an optimised mixture of CD4-APC, CD127-FITC and CD25-PE/Cy7) and 
fluorophore-streptavidin conjugates were obtained from BD Biosciences (San Jose, CA). 
Monoclonal antibody to FOXP3 (clone PCH101), and FOXP3 staining buffers were 
purchased from eBioscience (San Diego, CA), biotinylated horse anti-mouse Ig from 
VECTOR Laboratories (Burlingame, CA), and normal mouse serum from Dako 
(Glostrup, Denmark). The recombinant chemokines CCL17 (TARC; cat 228-11481-2) 
and CCL20 (MIP3-alpha; cat 228-11121-2) were obtained from RayBiotech (Norcross, 
GA). 
 
2.3 Generation of anti-PI16 Monoclonal Antibody 
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To generate PI16-expressing cells for immunization, the cloned full-length human PI16 
coding sequence from Open Biosystems (Thermo Scientific, Waltham, MA) was 
recloned into a Gateway pDEST40 vector (Invitrogen, Carlsbad, CA). Sub-confluent 
mouse L929 fibroblast cells (ATCC, Manassas, VA) were transiently transfected with the 
pDEST40/PI16 vector using Lipofectamine LTX (Invitrogen).  
Six-to-8 week old female Balb/c mice were initially immunised by the sub-cutaneous 
injection of 50 million pDEST40/PI16 transfected L929 cells in 500ul of PBS. The mice 
were boosted by sub-cutaneous injection of the same number of cells at four weeks and 
six weeks after the initial immunization. The mice were sacrificed four days after the 
final boost, and the spleen and a blood sample were collected. Procedures using mice 
were approved by the Animal Ethics Committee of the Children’s, Youth and Women’s 
Health Service, South Australia (AE667). 
Hybridomas were generated by fusing splenocytes with SP2/0 myeloma cells (ATCC) at 
a 10:1 ratio, essentially as described by Brooks et al. [20]. Colonies expressing antibody 
with similar reactivity to the PI16 polyclonal antibody were identified by flow cytometry 
and were expanded and twice-cloned by single-cell sorting using a FACSAria II cell 
sorter equipped with an Automated Cell Deposition Unit (BD Biosciences). By this 




Flow cytometry experiments using an unconjugated antibody were performed using a 
three-step “high sensitivity” staining protocol [21]. Briefly, PBMC were incubated with 
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the unconjugated primary antibody for 30min on melting ice, and then washed twice with 
PBS-azide. Biotinylated horse anti-mouse Ig reagent was added, incubated for 30min on 
wet ice, and the cells were washed twice with PBS-azide. Normal mouse serum was 
added (to block free Ig-binding sites on the anti-mouse Ig reagent) and incubated for 
10min, prior to the addition of the fluorophore-streptavidin conjugate detection reagent 
and any directly conjugated antibodies. No wash step was performed between the 
incubation of the mouse Ig and the addition of the final reagents. The cells were 
incubated as above and washed twice with PBS-azide  
In experiments where antibodies directed against intracellular antigens were used, the 
surface staining as described above was performed first, and the cells were then 
permeabilised and stained according to the manufacturer’s instructions. 
Stained cells were analysed using a FACSCanto flow cytometer (BD Biosciences). The 
resulting data were analysed using FlowJo software (TreeStar, Ashland, OR). 
 
2.5 Characterisation of Cytokine Secretion 
To identify the profile of cytokines secreted by subsets of CD4-positive cells defined 
using PI16 and CD25, we used a TH1/TH2/TH17 Cytometric Bead Array (CBA; BD 
Biosciences) to measure the levels of the cytokines IL2, IL4, IL6, IL10, IL17A, 
TNFalpha and IFNgamma in the supernatant of cells following in vitro stimulation. CD4-
positive lymphocytes were isolated from a peripheral blood buffy coat using the 
RosetteSep CD4+ T cell enrichment kit and were stained with antibodies to CD25 and 
PI16. The four CD4-positive subsets defined by CD25 and PI16 were sorted under 
aseptic conditions using a FACSAria II cell sorter.  
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To stimulate the cells, 5.0 x10^5 of a population of sorted cells were incubated with 
CD3/CD28 beads (Dynal T cell expander kit; Invitrogen) for 3 days. Unstimulated 
control cells were incubated without having the beads added. After incubation, the 
supernatant was collected and assayed for the cytokines using the TH1/TH2/TH17 CBA 
kit, according to the manufacturer’s instructions. For each subset, the cytokine 
concentrations were calculated by subtracting the concentration value for unstimulated 
cells from the value for stimulated cells. 
 
2.6 Assay of Lymphocyte Migration  
A Transwell-based chemotaxis assay was used to characterize the ability of subsets of 
CD4-positive cells defined using PI16 and CD25 to migrate in response to chemotactic 
signals. PBMC (10^6 cells in 100ul of media) were loaded into the upper chamber of 
Transwell plates with 5um pores (Corning), and chemokines (100ng/ml CCL17, 
100ng/ml CCL20 or 100ng/ml of each of CCL17 and CCL20 in a volume of 600ul) were 
added to the lower chamber. The cells were allowed to migrate for 2 hours at 37C. After 
the incubation, the cells from the upper and lower chambers were collected and stained 
with antibodies to CD4, CD25 and PI16. The proportion of cells in each of the four CD4-
positive lymphocyte subsets defined by CD25 and PI16 was determined by flow 
cytometry. 
 
2.7 Assay for Suppression of Effector Cell Proliferation 
To evaluate the ability of a candidate population to suppress the proliferation of an 
effector population, we used a mixed lymphocyte reaction (MLR), in which the cell 
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division of the Responder cells was analysed by CFSE dilution [22]. The PI16-positive 
and PI16-negative fractions of the CD4-positive/CD25-bright subset were isolated as 
Treg sub-populations by enriching CD4-positive lymphocytes from a peripheral blood 
buffy coat using the RosetteSep CD4+ T cell enrichment kit (Stem Cell Technologies, 
Vancouver, Canada), staining with antibodies to CD25 and PI16, and sorting under 
aseptic conditions using a FACSAria II cell sorter. CD25-negative Th cells were also 
collected to act as a control population with no regulatory activity. PBMC from this 
donor were irradiated (30Gy) for use as the MLR stimulator cells. CD4-positive/CD25-
negative “Effectors” from a second unmatched donor were used as the responder 
population in the MLR. These cells were isolated using magnetic-activated cell sorting 
(MACS; Miltenyi Biotech, Germany), and labelled with 1mM CFSE in PBS for 10mins 
at 37C.  
For the suppression assay, various numbers of the PI16-positive Treg, PI16-negative Treg 
or CD25-negative Th cells were mixed with 1x10
5
 stimulator cells and 2x10
4
 CFSE-
labelled Responder cells at Treg:Responder ratios of 1:1 (2x10
4





 Treg) and 1:8 (2.5x10
3
 Treg), in a total volume of 200ul of complete RPMI 
medium. The cell mixtures were stimulated for 5 days using 100ng/ml anti-CD3 
monoclonal antibody (OKT3; eBioscience). Control wells comprised stimulated labelled 
Responder cells alone or unstimulated labelled Responder cells alone. The proliferation 
of the Responder cells was visualised by the dilution of the CFSE fluorescence with cell 
division. The suppression of Responder cell proliferation by a Treg population was 
calculated by determining the relative suppression as described by Venken et al. [22]: 1-
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(%CFSE-low Responder cells in the presence of Treg / % CFSE-low Stimulated 
Responder cells in the absence of Treg), expressed as a percentage.  
 
2.8 Statistical Analysis 
The statistical significance of differences between the cell subsets were determined using 
the Wilcoxon matched-pairs test, using GraphPad Prism version 5.04 for Windows 







3.1 Distribution of PI16 expression by mononuclear cells. 
The monoclonal antibody CRCBT-02-001 was confirmed to have reactivity to PI16-
transfected NIH3T3 mouse fibroblasts, but not to untransfected NIH3T3 cells 
(Supplementary Figure 1). To determine the cellular distribution of PI16 by the major 
peripheral blood lymphocyte subsets, we stained PBMC with the CRCBT-002-01 
monoclonal antibody and antibodies to CD4, CD8 and CD19 (Supplementary Figure 2). 
This staining indicated that the majority of PI16-expressing cells were CD4-positive 
lymphocytes (typically approximately 20% of CD4-positive subset), with the remaining 
cells being CD8-positive T cells (approximately 10% of the CD8-bright subset). Almost 
no CD19-positive B cells were stained with the antibody to PI16. 
 
3.2 PI16 expression by CD4-positive T cells 
To characterise the expression of PI16 by Treg and other Th cells, we stained peripheral 
blood mononuclear cells with the CRCBT-002-01 monoclonal antibody and antibodies to 
CD4, CD25, CD127 and FOXP3. Using the gating strategy of Seddiki et al [13], we 
found that PI16 is expressed by a higher proportion the CD25-bright/CD127-dim Treg 
(average 28% PI16-positive) compared to the CD127-positive Th cell subset (average 
18.7% PI16-positive) (Figure 1A; n=15, p=0.006). Similar results are seen when PI16 
expression by the FOXP3-positive and FOXP3-negative subsets of CD4-positive 
lymphocytes is compared (Figure 1B; n=8; p=0.008). These results support the initial 
microarray data [20], but also indicate that the expression of PI16 is not confined to Treg. 
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3.3 Phenotype of PI16-positive Treg 
To further define the phenotype of the PI16-expressing subset of Treg, we stained 
lymphocytes with antibodies to CD4, CD25, PI16, CD45RA and FOXP3. Following the 
gating strategy described by Miyara [16], we found that the majority of cells in the 
FOXP3-positive “activated Treg” (Fraction 2) population expressed PI16, while few 
“resting Treg” (Fraction 1) expressed PI16 (Figure 2). We also examined the expression 
by PI16-positive Treg of other T cell markers, including CD45RO, CD45RA, CCR4 and 
CCR6 (Figure 3). The differential staining with suggests that the CD25-positive/PI16-
positive cells comprise a subset of memory Treg which is phenotypically distinct from 
both the PI16-negative Treg population and from the other PI16-positive Th cells.  
 
3.4 Correlation between PI16 and FOXP3 expression 
We next used antibodies to CD4, CD25, PI16 and FOXP3 to compare the expression of 
FOXP3 by the PI16-positive and PI16-negative Treg subsets. The mean fluorescence 
intensity (MFI) of FOXP3 staining was higher in the CD25-positive/PI16-positive 
fraction (average population MFI of 2759,) compared to the CD25-positive/PI16-negative 
fraction (average MFI of 1908) (Figure 4; n=6, p=0.03). The level of FOXP3 in the 
CD25-negative/PI16-positive fraction (average MFI of 884) was similar to the 
background levels of the CD25-negative/PI16-negative Effector cell fraction (average 
MFI of 659). The higher expression of FOXP3 suggests that the co-expression of PI16 
and CD25 may identify a specific subset of Treg in peripheral blood. 
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3.5 Chemotaxis by PI16-positive Treg 
To characterise the ability of PI16-positive memory Treg to respond to signals from a site 
of inflammation, we used a Transwell-based chemotaxis assay to examine the migration 
of PBMC towards CCL17 and CCL20. We found that the proportion of PI16-positive 
memory Treg in the lower Transwell chamber was increased after incubation in the 
presence of these chemokines either alone or in combination (Figure 5).  
 
3.6 Cytokine expression by PI16-positive Treg 
We utilised a TH1-Th2-TH17 Cytometric Bead Array (CBA) to determine which 
cytokines were expressed by PI16-expressing Treg following stimulation through the T 
cell receptor. These experiments showed that the cytokine expression profile of the PI16-
positive Treg cells was the same as the PI16-negative Treg cells, and that the PI16-
positive Th cells expressed the same cytokines as their PI16-negative counterparts (data 
not shown). 
 
3.7 Suppressor function of PI16-positive Treg 
We utilised a CFSE-based MLR assay to determine whether the PI16-expressing Treg 
were able to suppress the proliferation of CD3-stimulated Responder Th cells. Over 
several Treg:Thelper ratios, we found that freshly-isolated PI16-expressing Treg from 
peripheral blood were able to suppress the proliferation of stimulated CD25-negative Th 
cells to a similar extent as PI16-negative Treg from the same source (Figure 6). These 
data confirm that the PI16-positive/CD25-positive cells are functional Treg, but also 








Imbalances in the frequency and/or function of Treg have been reported in many diseases 
[23; 24; 25; 26]. The difficulty of using FOXP3 to isolate viable Treg for use in 
functional assays has lead to many candidate cell surface molecules being evaluated as 
surrogates for FOXP3 expression, but with limited success. As part of a gene discovery 
program, we identified PI16 as being over-expressed by cord-blood-derived Treg 
compared to Th cells [17]. We generated a monoclonal antibody to PI16, and using this 
we have determined that PI16 is expressed by 15-60% of CD25-bright CD4-positive 
lymphocytes in adult peripheral blood, all of which express high levels of the 
transcription factor FOXP3. Further analysis suggests that the PI16-positive memory 
Treg are part of the FOXP3-bright “activated Treg” (aTreg) population described by 
Miyara et al.[16]. 
 
In vitro analysis of sorted cells stimulated through CD3 and CD28 showed that the PI16-
positive Treg secrete a profile of cytokines which is similar to the PI16-negative Treg. 
Furthermore, the PI16-positive/CD25-bright CD4-positive cells were able to suppress the 
activation and proliferation of CD4-positive “Effector” cells, indicating that this 
population contains functional Treg. These results suggest that the ability of the Treg 
subset identified by the co-expression of PI16 and CD25 to regulate an immune response 
is equivalent to that of the PI16-negative Treg. 
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The differential expression of chemokine receptors is indicative of the migration 
capability of subsets of Th cells [27; 28], and can be used to identify functional subsets of 
Th cells [15; 29; 30]. We found that the profile of chemokine receptors expressed by the 
PI16-positive memory Treg was different to both the PI16-negative memory Treg and the 
other PI16-positive Th cells. The expression of chemokine receptors CCR4 and CCR6, 
and their ability to migrate toward CCL17 and CCL20 suggest that the PI16-positive 
memory Treg are able to respond to the same inflammation signals as Th17 cells. The co-
migration of Th17 cells and PI16-expressing memory Treg provides a means for the 
immune system to regulate the pro-inflammatory activity of the Th17 cells. Defects 
which prevent the migration of PI16-positive memory Treg to inflamed sites may 
exacerbate the development of autoimmune pathologies. 
 
In conclusion, we have determined that the co-expression of PI16 and CD25 identifies a 
distinct subset of functional FOXP3-positive memory Treg, which demonstrate an 
enhanced migration in response to the chemokines CCL17 and CCL20. This suggests that 
PI16-positive memory Treg are capable of migrating toward the same sites of 
inflammation as other Th cells which express these receptors, including pro-
inflammatory Th17 cells, and that the PI16-positive Treg may be preferentially recruited 
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Figure 1: Expression of cell surface PI16 by Treg and Th cell subsets of CD4-positive 
lymphocytes, demonstrated using by the anti-PI16 monoclonal antibody CRCBT-02-001. 
Only the CD4-positive lymphocytes are shown. a. (A) Cell surface PI16 is present on a 
higher proportion of CD25-bright/CD127-dim Treg (upper row, centre panel) than 
CD127-positive Th cells (upper row, right panel). The values shown in each gate are the 
mean and SD of the percent in that gate for n=15 different donors. (B) Cell surface PI16 
is present on a higher proportion of FOXP3-positive CD4-positive lymphocytes (lower, 
centre panel) than FOXP3-positive CD4-positive lymphocytes (lower row, right panel). 
The values shown in each gate are the mean and SD of the percent in that gate for n=8 
different donors. 
 
Figure 2: Expression of PI16 and FOXP3 by six fractions of naive and memory Treg 
defined using the gating strategy described by Miyara [16]. Only the CD4-positive 
lymphocytes are shown. The values shown are the means and SD for n=5 different 
donors. The fractions of CD4-positive lymphocytes (Fraction 1 (Fr1) to Fraction 6) were 
defined using the expression of CD45RA and CD25. The expression of PI16 (CRCBT-
02-001) and FOXP3 by the cells in each of these fractions is shown. In each fraction, the 
PI16-positive and PI16-negative cells express similar levels of FOXP3, with the highest 
levels of FOXP3 expression seen in the memory aTreg fraction (Fraction 2). 
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Figure 3: Phenotype of CD4-positive lymphocytes defined using the co-expression of 
CD25 and PI16 (CRCBT-02-001). Only the CD4-positive lymphocytes are shown. The 
values shown are the means and SD for n=7 different donors. The four subsets of CD4-
positive lymphocytes were defined as shown in Figure 2. (A) Co-expression of CD45RA 
and CD45RO by the four subsets defined using the co-expression of CD25 and PI16, 
showing that the cells in the CD25-positive/PI16-positive subset have a memory 
(CD45RO-positive/CD45RA-negative) phenotype. (B) Expression of CD45RO and 
CCR4 by the four subsets, showing that CCR4 is expressed by a higher proportion of 
memory CD25-positive/PI16-positive cells, compared to the memory component of the 
other subsets. (C) Expression of CD45RO and CCR6 by the four subsets, showing that 
CCR6 is expressed by a higher proportion of memory CD25-positive/PI16-positive cells, 
compared to the memory component of the other subsets.  
 
Figure 4: Expression of FOXP3 by subsets of CD4-positive lymphocytes defined using 
the co-expression of CD25 and PI16 (CRCBT-02-001). Only the CD4-positive 
lymphocytes are shown. The values shown are the means and SD for n=6 different 
donors. The cells in the CD25-positive/PI16-positive Treg fraction (heavy solid line; 
average population MFI of 2759) express higher levels of FOXP3 than cells in the CD25-
positive/PI16-negative Treg fraction (dashed line; average MFI of 1908). FOXP3 staining 
was lowest in the CD25-negative/PI16-positive (light solid line; average MFI of 884) and 
CD25-negative/PI16-negative (dotted line; average MFI of 659) populations. 
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Figure 5: Migration of subsets of CD4-positive lymphocytes defined using the co-
expression of CD25 and PI16 in response to the chemokines CCL17 and CCL20. The 
graphs show the proportion of CD4-positive cells in each subset in the upper chambers 
(light bars) and lower chambers (dark bars) after the incubation, and the error bars show 
the SEM for six experiments using cells from different donors. The data indicate that 
there is a preferential migration of the CD25-positive/PI16-positive cells in response to 
each of the chemokines.  
 
Figure 6: Suppression of CD3 stimulation-induced proliferation of CD4-positive/CD25-
negative Responder cells by freshly isolated PI16-positive and PI16-negative Treg. The 
PI16-positive and PI16-negative Treg were sorted using the gates shown in Figure 2. (A) 
CFSE fluorescence of the Responder Th cells in the presence of Suppressor cells 
comprising PI16-positive Treg (upper row), PI16-negative Treg (middle row) or control 
CD25-negative Th cells (bottom row) at Suppressor to Responder ratios from 1:1 (left 
column) to 1:8 (right column). Data representative of 5 experiments are shown. The 
region marker and percentages indicate the proportion of cells which did not proliferate 
(right side region) and cells that have divided (left side region). The far right panels show 
the CFSE staining of the unstimulated Responder Th cells (left-side plot) and CD3-
stimulated Responder Th cells in the absence of other cells (right-side plot). (B) Relative 
suppression Responder Th proliferation by PI16-positive and PI16-negative Treg. The 
values shown are the mean and SEM for 4 different donors. The results suggest that fresh 
adult PI16-positive and PI16-negative Teg have the same capacity to suppress the 
proliferation of the Responder cells. 
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